
 SENDERRA <i>Specialty Pharmacy</i> 1301 E. Arapaho Rd., Ste. 101 Richardson, TX 75081 <i>This prescription form is to be sent & received via fax</i>	Pediatric Dermatology Enrollment Form A-H Physician Offices Call: 855-460-7928 Fax: 888-777-5645		Prescriber: Supervising Physician: Address: Phone: Contact:		NPI: NPI: Tax ID: Fax:	
---	--	--	--	--	---	--

PATIENT INFORMATION								
Name:		<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other		DOB: ____/____/____		SS#: ____-____-____		
Street:			City:		State:		ZIP:	
Phone:		Alt. Phone:		<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: ____		Wt.: ____ Ht.: ____		

PRESCRIPTION			
Has the patient received a loading dose/starter kit? <input type="checkbox"/> Yes Start Date: ____/____/____ <input type="checkbox"/> No SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: ____			
Drug		Directions & Quantity	Refills
Cosentyx®	<input type="checkbox"/> 75 mg Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 75 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: 5) ***WEIGHT REQUIRED*** <input type="checkbox"/> MAINTENANCE: Inject 75 mg SQ every 4 weeks (Quantity: 1) ***Intended for weight < 50 kg/110 lbs***	
	<input type="checkbox"/> 150 mg Sensoready Pen	<input type="checkbox"/> INITIAL: Inject 150 mg SQ at week 0, 1, 2, 3, and 4 (Quantity: 5) ***Intended for weight ≥ 50 kg/110 lbs*** <input type="checkbox"/> MAINTENANCE: Inject 150 mg SQ every 4 weeks (Quantity: 1)	
	<input type="checkbox"/> 150 mg Pre-filled Syringe		
Enbrel®	<input type="checkbox"/> SureClick® Pen	<input type="checkbox"/> Inject ____ mg (0.8mg/kg x ____ kg SQ every week) (Quantity: QS 1 month) ***WEIGHT REQUIRED*** ***Intended for weight < 63 kg/138 lbs***	
	<input type="checkbox"/> Mini® with AutoTouch®		
	<input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg <input type="checkbox"/> 25 mg Vial	<input type="checkbox"/> Inject 50 mg SQ every week (Quantity: 4) ***Intended for weight ≥ 63 kg/138 lbs***	
Humira® Citrate Free	<input type="checkbox"/> HS Starter Kit	<input type="checkbox"/> INITIAL: Inject 160 mg SQ at day 1, then 80 mg on day 15 (Quantity: QS 28 days) ***WEIGHT REQUIRED*** <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week starting at day 29 (Quantity: 4) ***Intended for weight ≥ 60 kg/132 lbs***	
	<input type="checkbox"/> Pen		
	<input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> MAINTENANCE: Inject 80 mg SQ every other week starting at day 29 (Quantity: 2)	
	<input type="checkbox"/> Adolescent HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 80 mg SQ at day 1, 40 mg at day 8, then 40 mg every other week (Quantity: QS 28 days) ***Intended for weight 30 kg/66 lbs to <60 kg/132 lbs*** <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)	

MEDICAL INFORMATION					
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY					
PREVIOUS THERAPIES: <input type="checkbox"/> Methotrexate <input type="checkbox"/> Stelara <input type="checkbox"/> Humira <input type="checkbox"/> Enbrel <input type="checkbox"/> _____	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: _____ _____ _____ _____	 Affected Areas <input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: _____ BSA ____%	
PHOTOTHERAPY <input type="checkbox"/> UVA /UVB <input type="checkbox"/> Patient cannot afford	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: _____ _____ _____		
Date of Diagnosis: ____/____/____ <input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis) <input type="checkbox"/> L73.2 Hidradenitis suppurativa <input type="checkbox"/> Other: _____					
Active TB ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____ Active Hep B ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____				Allergies:	
Additional Clinical Information:					

American Academy of Dermatology Consensus Statement on Psoriasis Therapies	
<input type="checkbox"/> Psoriasis is covering greater than 10% of body surface area <input type="checkbox"/> Psoriasis is on palms, soles, head and neck, or genitalia <input type="checkbox"/> Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints <input type="checkbox"/> Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships	
INJECTION TRAINING	
<input type="checkbox"/> Patient has received pen and injection training <input type="checkbox"/> Physician's office to provide injection training <input type="checkbox"/> Senderra to coordinate injection training	
PRESCRIBER SIGNATURE	
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.	
Prescriber:	Date: ____/____/____

CONFIDENTIALITY NOTICE	
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.	